Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

AMAG Pharmaceuticals Inc (NASDAQ:AMAG)

34.00
Delayed Data
As of Dec 09
 +0.15 / +0.44%
Today’s Change
17.92
Today|||52-Week Range
36.23
+12.62%
Year-to-Date
SECTOR
Health Technology
INDUSTRY
Biotechnology
MARKET CAP
$1.2B

Company Description

AMAG Pharmaceuticals, Inc. is a biopharmaceutical company that focuses on the development and commercialization of a therapeutic iron compound to treat iron deficiency anemia. It focuses on the development and commercialization of Feraheme injection for intravenous or IV, use to treat iron deficiency anemia or IDA. The company engages in manufacture, development and commercialization of products derived from its proprietary technology for use in treating human diseases. The company was founded on 9th, November 1981 and is headquartered in Waltham, MA.

Contact Information

AMAG Pharmaceuticals, Inc.
1100 Winter Street
Waltham Massachusetts 02451
P:(617) 498-3300
Investor Relations:
(617) 498-2864

Employees

Shareholders

Mutual fund holders64.69%
Other institutional57.42%
Individual stakeholders14.58%

Top Executives

William K. HeidenChief Executive Officer & Director
Frank E. ThomasPresident & Chief Operating Officer
Edward H. MylesChief Financial Officer, Treasurer & Senior VP
Nathan McBrideChief Information Officer & Senior VP-Innovation
Julie KropChief Medical Officer & SVP-Regulatory Affairs